Johnson & Johnson (NYSE:JNJ) – Research analysts at Jefferies Group issued their Q3 2016 earnings estimates for shares of Johnson & Johnson in a research note issued to investors on Thursday. Jefferies Group analyst J. Holford expects that the brokerage will earn $1.71 per share for the quarter. Jefferies Group has a “Hold” rating and a $115.00 price target on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2016 earnings at $6.72 EPS and FY2017 earnings at $6.78 EPS.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.06. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The firm had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $17.98 billion.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Several other research firms have also recently issued reports on JNJ. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target on the stock in a research note on Monday, August 22nd. Leerink Swann reaffirmed an “outperform” rating and set a $140.00 price target (up from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, September 20th. RBC Capital Markets reissued an “outperform” rating and issued a $133.00 target price (up from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Finally, BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Thursday, August 25th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $120.20.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 117.56 on Friday. The stock has a market capitalization of $321.63 billion, a P/E ratio of 21.91 and a beta of 0.62. Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07. The company’s 50-day moving average is $118.72 and its 200 day moving average is $117.37.

A number of institutional investors have recently added to or reduced their stakes in JNJ. Americafirst Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter worth approximately $101,000. Tuttle Tactical Management LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at about $103,000. Lenox Wealth Management Inc. increased its position in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. increased its position in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. purchased a new position in shares of Johnson & Johnson during the second quarter valued at about $127,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the transaction, the vice president now owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the transaction, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.